Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients

被引：37
|
作者：
Wang, Zhan [1 ]
Chen, Juan [2 ,3 ]
Zhong, Mei-Zuo [1 ]
Huang, Juan [4 ]
Hu, Yuan-Ping [4 ]
Feng, De-Yun [5 ]
Zhou, Zhi-Jiao [6 ]
Luo, Xiao [7 ]
Liu, Zhao-Qian [2 ,3 ]
Jiang, Wu-Zhong [1 ]
Zhou, Wei-Bing [1 ]
机构：
[1] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha 410008, Hunan, Peoples R China
[3] Cent South Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha 410078, Hunan, Peoples R China
[4] Hunan Prov Clin Meditech Res Ctr Breast Canc, Changsha 410008, Hunan, Peoples R China
[5] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Hunan, Peoples R China
[6] Cent South Univ, Xiangya Hosp 3, Dept Pathol, Changsha 410013, Hunan, Peoples R China
[7] Cent South Univ, Xiangya Hosp 3, Dept Pain, Changsha 410013, Hunan, Peoples R China
来源：
CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2017年 / 79卷 / 03期
基金：
中国国家自然科学基金;
关键词：
ANLN; Breast cancer; Anthracycline; Prognosis; BINDING PROTEIN ANILLIN; DNA ADDUCTS; CYCLIN D1; ADJUVANT THERAPY; DOXORUBICIN; REPAIR; CYCLOPHOSPHAMIDE; EXPRESSION; RECOMBINATION; ACTIVATION;
D O I：
10.1007/s00280-017-3248-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
To investigate the associations of ANLN expression with prognosis of breast cancer and clinical outcome of anthracycline-based chemotherapy. This study enrolled 308 breast cancer patients in which 264 of them received anthracycline-based chemotherapy. Immunohistochemistry was used to detect ANLN expression level of the patients. Clinical characteristics of the patients were collected, and associations of ANLN expression with prognosis were analyzed. Our results showed that ANLN expression was associated with survival of breast cancer patients, and it was also related to clinical outcome of patients received anthracycline-based chemotherapy. Breast cancer patients with high expression of ANLN would have poor prognosis and poor clinical outcome to anthracycline-based chemotherapy. ANLN could be an independent prognosis predictor for breast cancer, and its expression might be used to predict the anthracycline-based chemotherapy clinical outcome in breast cancer patients.
引用
收藏
页码：535 / 543
页数：9
相关论文
共 50 条
  • [31] HPD overexpression predicts poor prognosis in breast cancer
    Wang, Xuanyu
    Shang, Yongjun
    Yang, Lina
    Tan, Xiaoyu
    Zhang, Huamin
    Shan, Changliang
    Liu, Shuangping
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (09)
  • [32] Adjuvant anthracycline-based chemotherapy for early breast cancer: do the dose and schedule matter?
    Mano, MS
    Awada, A
    Kerr, J
    Canney, P
    CANCER TREATMENT REVIEWS, 2005, 31 (02) : 69 - 78
  • [33] Rank-based predictors for response and prognosis of neoadjuvant taxane-anthracycline-based chemotherapy in breast cancer
    Zhang, Lin
    Hao, Chunxiang
    Shen, Xiaopei
    Hong, Guini
    Li, Hongdong
    Zhou, Xianxiao
    Liu, ChunYang
    Guo, Zheng
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (02) : 361 - 369
  • [34] FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer
    Mingyou Xing
    Jun Wang
    Qin Yang
    Yu Wang
    Jiansha Li
    Jing Xiong
    Sheng Zhou
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 861 - 872
  • [35] Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy
    Wafaa S. El-Sherbeny
    Nesreen M. Sabry
    Radwa M. Sharbay
    Journal of Echocardiography, 2019, 17 : 76 - 83
  • [36] Longitudinal rotation: a new way to detect the cardiotoxicity of anthracycline-based chemotherapy in breast cancer patients
    Huang, Jun
    Yan, Zi-Ning
    Rui, Yi-Fei
    Shen, Dan
    Fan, Li
    Chen, Dong-Liang
    ONCOTARGET, 2017, 8 (41) : 70072 - 70083
  • [37] Fragmented QRS formation and its predictors in patients with breast cancer receiving anthracycline-based chemotherapy
    Dural, Muhammet
    Demir, Lutfiye
    Babayigit, Erdi
    Junushova, Bermet
    Mert, Kadir Ugur
    Ulus, Taner
    Cavusoglu, Yuksel
    Yildiz, Bulent
    Dincer, Murat
    Gorenek, Bulent
    JOURNAL OF ELECTROCARDIOLOGY, 2019, 54 : 5 - 9
  • [38] Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients
    Chirivella, Isabel
    Bermejo, Begona
    Insa, Amelia
    Perez-Fidalgo, Alejandro
    Magro, Ana
    Rosello, Susana
    Garcia-Garre, Elisa
    Martin, Paloma
    Bosch, Ana
    Lluch, Ana
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 479 - 484
  • [39] Prognostic implication of HSPA (HSP70) in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy
    Nadin, Silvina B.
    Sottile, Mayra L.
    Montt-Guevara, Maria M.
    Gauna, Gisel V.
    Daguerre, Pedro
    Leuzzi, Marcela
    Gago, Francisco E.
    Ibarra, Jorge
    Dario Cuello-Carrion, F.
    Ciocca, Daniel R.
    Vargas-Roig, Laura M.
    CELL STRESS & CHAPERONES, 2014, 19 (04) : 493 - 505
  • [40] Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy
    Yun, J.
    Kim, K. H.
    Kang, E. S.
    Gwak, G. -Y.
    Choi, M. S.
    Lee, J. E.
    Nam, S. J.
    Yang, J. -H.
    Park, Y. H.
    Ahn, J. S.
    Im, Y. -H.
    BRITISH JOURNAL OF CANCER, 2011, 104 (04) : 559 - 563
12345